Evaluation of antibody response in horses after vaccination with an inactivated Getah virus vaccine using an accelerated immunization schedule

2021 ◽  
pp. 103396
Author(s):  
Hiroshi Bannai ◽  
Masataka Tominari ◽  
Yoshinori Kambayashi ◽  
Manabu Nemoto ◽  
Koji Tsujimura ◽  
...  
Keyword(s):  
Antibody Response ◽  
Virus Vaccine ◽  
Immunization Schedule ◽  
Getah Virus

scholarly journals Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax® FIV)

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 470
Author(s):  
Mark Westman ◽  
Dennis Yang ◽  
Jennifer Green ◽  
Jacqueline Norris ◽  
Richard Malik ◽  
...  
Keyword(s):  
Antibody Response ◽  
Virus Vaccine ◽  
Point Of Care ◽  
Primary Vaccination ◽  
Antibody Responses ◽  
Blood Samples ◽  
Study Results ◽  
Elisa Testing ◽  
Primary Antibody Response ◽  
Residual Blood

Although the antibody response induced by primary vaccination with Fel-O-Vax® FIV (three doses, 2–4 weeks apart) is well described, the antibody response induced by annual vaccination with Fel-O-Vax® FIV (single dose every 12 months after primary vaccination) and how it compares to the primary antibody response has not been studied. Residual blood samples from a primary FIV vaccination study (n = 11), and blood samples from cats given an annual FIV vaccination (n = 10), were utilized. Samples from all 21 cats were tested with a commercially available PCR assay (FIV RealPCRTM), an anti-p24 microsphere immunoassay (MIA), an anti-FIV transmembrane (TM; gp40) peptide ELISA, and a range of commercially available point-of-care (PoC) FIV antibody kits. PCR testing confirmed all 21 cats to be FIV-uninfected for the duration of this study. Results from MIA and ELISA testing showed that both vaccination regimes induced significant antibody responses against p24 and gp40, and both anti-p24 and anti-gp40 antibodies were variably present 12 months after FIV vaccination. The magnitude of the antibody response against both p24 and gp40 was significantly higher in the primary FIV vaccination group than in the annual FIV vaccination group. The differences in prime versus recall post-vaccinal antibody levels correlated with FIV PoC kit performance. Two FIV PoC kits that detect antibodies against gp40, namely Witness® and Anigen Rapid®, showed 100% specificity in cats recently administered an annual FIV vaccination, demonstrating that they can be used to accurately distinguish vaccination and infection in annually vaccinated cats. A third FIV PoC kit, SNAP® Combo, had 0% specificity in annually FIV-vaccinated cats, and should not be used in any cat with a possible history of FIV vaccination. This study outlines the antibody response to inactivated Fel-O-Vax® FIV whole-virus vaccine, and demonstrates how best to diagnose FIV infection in jurisdictions where FIV vaccination is practiced.

scholarly journals Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus

1981 ◽  
Vol 87 (2) ◽  
pp. 201-209 ◽  
Author(s):  
N. Masurel ◽  
P. Ophof ◽  
P. de Jong
Keyword(s):  
New Jersey ◽  
Side Effects ◽  
Antibody Response ◽  
Virus Vaccine ◽  
Influenza A ◽  
H1n1 Virus ◽  
Vaccine Dose ◽  
Booster Vaccination ◽  
Booster Immunization ◽  
Group A

SummaryA group of 269 pupils of the Harbour and Transport Training Institute in Rotterdam (group A), aged 13–20 years, and of 109 patients of the Dr Mr Willem van den Bergh Foundation at Noordwijk (group B), aged 11–21 years, were immunized with a whole virus vaccine containing 10, 20, or 40 μg HA of A/USSR/92/77 (H1N1) influenza virus. A booster vaccination was administered 6 weeks later with 20 μg HA of the same virus. Many of the participants had been immunized during the two preceding years with a whole virus vaccine containing A/New Jersey/8/76 (H1N1) (A/NJ/76) virus. The side-effects, mostly of a moderate nature, increased with the dose of virus in the vaccine. In group A side effects were least frequent in the vaccinees who had never received A/NJ/76 vaccine. A single dose of A/USSR/77 vaccine did not produce satisfactory levels of homologous antibodies. After booster immunization with 20 μg HA of A/USSR/77 virus participants showed a higher homologous antibody response in all vaccine-dose groups if they had not been immunized with A/NJ/76 virus in previous years. After primary and especially after booster immunization with A/USSR/77 virus, a very high response against A/NJ/76 virus and adequate levels of A/NJ/76 antibody were found in participants who had been immunized previously with A/NJ/76 virus. Those who had not been immunized with this virus previously showed no or a very low antibody response to A/NJ/76 virus.

scholarly journals T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Yonas Bekele ◽  
Desalegn Yibeltal ◽  
Kidist Bobosha ◽  
Temesgen E. Andargie ◽  
Mahlet Lemma ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antibody Response ◽  
Virus Vaccine ◽  
T Follicular Helper Cells ◽  
Helper Cells ◽  
Follicular Helper ◽  
B Virus ◽  
Hepatitis B Virus Vaccine ◽  
Hiv 1

The effect of Trypanosoma congolenseand T vivaxinfections on the antibody response of cattle to live rinderpest virus vaccine

1980 ◽  
Vol 28 (2) ◽  
pp. 264-266 ◽  
Author(s):  
F.R. Rurangirwa ◽  
E.Z. Mushi ◽  
H. Tabel ◽  
I.R TiZard ◽  
G.J. Losos
Keyword(s):  
Antibody Response ◽  
Virus Vaccine ◽  
Rinderpest Virus

THE ANTIBODY RESPONSE IN MAN TO A QUADRIVALENT INFLUENZA VIRUS VACCINE

1955 ◽  
Vol 1 (4) ◽  
pp. 249-255
Author(s):  
Barbara K. Buchner ◽  
D. B. W. Reid ◽  
G. Dempster
Keyword(s):  
Influenza Virus ◽  
Antibody Response ◽  
Virus Vaccine ◽  
Influenza Virus Vaccine ◽  
The Other ◽  
Type B ◽  
Strain Type ◽  
Antibody Levels ◽  
Subcutaneous Inoculation

The antibody response to the subcutaneous inoculation of a single 1 ml. dose of a quadrivalent formalin-killed influenza virus egg vaccine has been measured. The vaccine used contained two A prime components and an A and a B component. Satisfactory responses were obtained two weeks after inoculation to the A and B components and to one of the A prime strains (FM1). A poor antibody response was noted to the other A prime strain incorporated in the vaccine (FW50). The highest levels were obtained with the Lee strain (Type B) which also stimulated an antibody rise to a recently isolated Type B strain. Antibody levels were maintained for at least 12 weeks. Treatment of the sera with RDE was found to influence the results obtained with the FM1 strain used.

Sign in / Sign up

Export Citation Format

Share Document